Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

NCT04177355 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

127

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: BG505 SOSIP.664 gp140
BIOLOGICAL: Placebo
BIOLOGICAL: 3M-052-AF
BIOLOGICAL: CpG 1018
BIOLOGICAL: GLA-LSQ
BIOLOGICAL: Alum (Aluminum Hydroxide Suspension)
BIOLOGICAL: Trimer 4571

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]